FLT3 and acute myeloid leukemia: Therefore, no definitive conclusion on which is the better treatment in s‐AML and t‐AML with FLT3‐activating mutations can be drawn and, until comparative trial results are available, the decision should be individualized to the single patients considering cytogenetics, performance status and the presence of other mutations [37].